John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), today released the following statement ahead of an expected vote in the U.S. House of Representatives on a ...

Today the dispute settlement panel formed under the United States-Mexico-Canada Agreement (USMCA) issued a final ruling related to Mexico's restrictions on the importation of genetically modified (GM) ...

Before we head out for the holidays, we're back with some breaking news about a few of BIO's legislative priorities. Happy Holidays and Happy New Year! We'll see you in 2025 (unless there's major ...

BIO’s new and improved partnering system – BIO Partnering – is debuting at the 2025 BIO CEO & Investor Conference (Feb 10-11 in New York, NY). Join BIO’s VP of Partnering, Mackensie Vernetti, for a ...

Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry's economic ...

BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities. "Manufacturers should have the choice to effectuate ...

Today, the Biotechnology Innovation Organization (BIO) named Sarah Alspach as its new executive vice president and chief communications officer. Alspach, a communications veteran, will join BIO’s ...

Prior to the case study exercise, Silas Buchanan Founding CEO of the Institute for eHealth Equity will provide a framework to use for underserved-community outreach and how to avoid failure points. He ...

Pamela Torpey is a Principal Counsel in the Global Intellectual Property Department at Sanofi, bringing over 25 years of experience in the biotechnology and pharmaceutical industries. Since joining ...

Barbara Fiacco is a Partner, co-chair of the Intellectual Property Department and co-chair of the Patent, Trade Secrets, and Related Rights Litigation Practice at Foley Hoag LLP. In her practice, ...

Javeed Froozan’s corporate development experience spans over 25 years in early stage, growth, and large biopharma and health tech firms. This includes acquiring companies, products and technologies in ...

Scott Carmer is the former CEO at NexImmune – a Johns Hopkins incubated spin-out which was based on innovative science developed in the lab of co-founder, Jonathan Schneck. During an eight-year career ...